NONMEM Users Network Archive

Hosted by Cognigen

NM7 question

From: Sam Liao <sliao>
Date: Wed, 4 Nov 2009 19:31:09 -0500

Dear NONMEM team:

To run the M3 method to handle BQL samples, we have to use method=LAPLACIAN
NUMERICAL SLOW in NM6. Can we use the new methods in NM7 such as IMP, SAEM
or BAYES if we have to run the M3 method?


Best regards,

Sam Liao

Pharmax Reseach


From: owner-nmusers
Behalf Of Nick Holford
Sent: Wednesday, November 04, 2009 6:43 PM
To: nmusers
Subject: Re: [NMusers] advan8 vs. advan13 (CORRECTION)



Thanks to Peiming Ma and Thuy Vu for pointing out an error in my attempt to
transform bioavailability into its logit.

The logit transformation of a probability is ln(P/(1-P)) i.e. the log of the
odds ratio. The reverse transform is correct i.e. exp(logit) is the odds
ratio and P is then OR/(1+OR) (or 1/1+exp(-logit)).

If THETA(1) is the bioavailability then this is (I hope) the correct
transformation of THETA(1) and reverse transform to get the individual
bioavailability with a random effect constrained to be within 0 and 1.

MU_1=LOG(THETA(1)/(1-THETA(1)) ; logit of population bioavailability

EXPP=MU_1+ETA(1) ; add random effect

BIO=1/(1+EXP(-EXP(EXPP))) ; individual bioavailability


Nick Holford, Professor Clinical Pharmacology
Dept Pharmacology & Clinical Pharmacology
University of Auckland,85 Park Rd,Private Bag 92019,Auckland,New Zealand
tel:+64(9)923-6730 fax:+64(9)373-7090 mobile:+64(21)46 23 53
email: n.holford

Received on Wed Nov 04 2009 - 19:31:09 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: